Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334182 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL21548014 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL22113161 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL1573636 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL13713095 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL372614 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL704299 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL7624931 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL1110550 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL3368724 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-0422846-B1 | Aroyl-ureas | WYETH JOHN & BROTHER LTD (GB) | 1994-02-16 | — | — | EP | claimed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | claimed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | claimed |
| EP-0422846-A2 | Aroyl-ureas | JOHN WYETH & BROTHER LIMITED (GB) | 1991-04-17 | — | — | EP | claimed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | Theravance Biopharma R&D LP, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| EP-0254584-A2 | Azabicyclic compounds, process for their preparation, and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1988-01-27 | — | — | EP | disclosed |
| EP-0247266-A1 | Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1987-12-02 | — | — | EP | disclosed |
| EP-0220339-A1 | Azabicycloalkyl derivatives | BEECHAM GROUP PLC (GB) | 1987-05-06 | — | — | EP | disclosed |
| US-4443452-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | CYP2C9 1233/4885LMNA 1562/4885SLC6A2 2937/4885 |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | JAK1, JAK3, JAK2 | CYP2C9 1105/4885LMNA 2149/4885SLC6A2 4832/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | CYP2C9 4046/4885LMNA 4843/4885SLC6A2 4186/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | CYP2C9 3256/4885LMNA 1762/4885SLC6A2 1504/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | CYP2C9 436/4885LMNA 2720/4885SLC6A2 4412/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | CYP2C9 2409/4885LMNA 4776/4885SLC6A2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.